VIDEO: NT-501 reduces progression of macular telangiectasia type 2
Click Here to Manage Email Alerts
PARK CITY, Utah — In this Healio Video Perspective from Clinical Trials at the Summit, Thomas Aaberg Jr., MD, of Neurotech Pharmaceuticals, discusses NT-501, an encapsulated cell therapy in development for macular telangiectasia type 2.
“The backbone of our technology are human [retinal pigment epithelium] cells that we can genetically engineer to produce a variety of therapeutic proteins,” Aaberg said, adding that NT-501 (revakinagene taroretcel) is one such device that has been engineered to produce ciliary neurotrophic factor.
Two parallel phase 3 trials of NT-501 met their primary outcomes, which measured area of ellipsoid zone loss using OCT.
The FDA granted priority review of the biologics license application for NT-501 in June and assigned it a PDUFA goal date of Dec. 17.
Collapse
Aaberg T. Efficacy, safety and durability of revakinagene taroretcel for macular telangiectasia. Presented at: Clinical Trials at the Summit; June 8, 2024; Park City, Utah.
Read more about
Click Here to Manage Email Alerts